BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 29221961)

  • 1. Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia.
    Clavijo LC; Al-Asady N; Dhillon A; Matthews RV; Caro J; Tun H; Rowe V; Shavelle DM
    Cardiovasc Revasc Med; 2018 Jul; 19(5 Pt A):516-520. PubMed ID: 29221961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switch to Ticagrelor in critical limb ischemia antiplatelet study (STT-CLIPS).
    Clavijo LC; Dhillon A; Al-Asady N; Matthews RV; Caro J; Tun H; Rowe V; Shavelle DM
    Cardiovasc Revasc Med; 2018; 19(3 Pt B):319-323. PubMed ID: 29329963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
    Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
    Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
    Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
    Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
    Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
    Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity.
    Gaglia MA; Torguson R; Pokharel S; Pakala R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2013; 14(2):76-80. PubMed ID: 23375617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study.
    Park Y; Jeong YH; Tantry US; Ahn JH; Kim KH; Koh JS; Park JR; Hwang SJ; Kwak CH; Hwang JY; Gurbel PA
    Thromb Haemost; 2014 Dec; 112(6):1198-208. PubMed ID: 25182660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet function testing: dead or alive.
    Helten C; Naguib D; Dannenberg L; Pöhl M; Ayhan A; Hohlfeld T; Levkau B; Kelm M; Zeus T; Polzin A
    J Thromb Haemost; 2018 May; 16(5):984-986. PubMed ID: 29512292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
    Jakubowski JA; Angiolillo DJ; Zhou C; Small DS; Moser BA; Ten Berg JM; Brown PB; James S; Winters KJ; Erlinge D
    Thromb Res; 2014 Sep; 134(3):552-7. PubMed ID: 25022828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High on-treatment platelet reactivity in patients with ischemic cerebrovascular disease: assessment of prevalence and stability over time using four platelet function tests.
    Jover E; Rodríguez JM; Bernal A; Arroyo AB; Iniesta JA; Guiú IS; Martínez C; Vicente V; Lozano ML; Rivera J
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):604-11. PubMed ID: 24717421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Window of Clopidogrel and Ticagrelor in Patients With Critical Limb-Threatening Ischemia.
    Dhillon AS; Caro J; Tun H; Armstrong DG; Rowe V; Shavelle DM; Clavijo LC
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):158-163. PubMed ID: 31550912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
    JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease.
    Bernlochner I; Jaitner J; Fries V; Dommasch M; Mayer K; Ott I; Langwieser N; Fusaro M; Laugwitz KL; Kastrati A; Ibrahim T
    Vasa; 2016; 45(2):155-61. PubMed ID: 27058802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the response to aspirin and clopidogrel vary over 6 months in patients with ischemic heart disease?
    Khanna V; Mikael R; Thayalasamy K; Sambu N; Dimitrov BD; Englyst N; Calver AL; Corbett S; Gray H; Simpson IA; Wilkinson JR; Curzen N
    J Thromb Haemost; 2015 Jun; 13(6):920-30. PubMed ID: 25809653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
    Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel.
    Bonello L; Mancini J; Pansieri M; Maillard L; Rossi P; Collet F; Jouve B; Wittenberg O; Laine M; Michelet P; Bessereau J; Lemesle G; Dignat-George F; Paganelli F; Camoin-Jau L
    J Thromb Haemost; 2012 Oct; 10(10):1999-2005. PubMed ID: 22863374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.
    Ueno M; Ferreiro JL; Tomasello SD; Tello-Montoliu A; Capodanno D; Seecheran N; Kodali M; Dharmashankar K; Desai B; Charlton RK; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2011 Aug; 4(8):905-12. PubMed ID: 21851906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.